West Pharmaceutical Services, Inc. WST

Full chart Compare
Set alert

Price alert · WST

All alert types
406.99 USD -0.89 (-0.22%)

At closeNov 3, 2026, 4:42 PM EST

406.99 0.00 0.00%

After hours · Nov 3, 4:42 PM ET

406.05 Day range 416.23
230.95 52-week range 416.67
YTD
+47.92%
1 year
+45.47%
Market cap
28.35B
Revenue (ttm)
3.40B
Profit margin
18.81%
EPS (ttm)
8.89
Shares out
69.66M
P/E ratio
45.78
Forward P/E
40.78
Dividend
1.04 (0.26%)
Ex-dividend date
Nov 9, 2026
YTD return
+47.92%
1-year return
+45.47%
Volume
1.08M
Avg volume
584.68K
Open
407.39
Previous close
407.88
Day's range
406.05 – 416.23
52-week range
230.95 – 416.67
Beta
1.14
Analysts
Strong Buy
Price target
471.00 (+15.7%)
Earnings date
Feb 11, 2027

YTD +130.59 (+47.25%)

300400Feb 3Apr 6Jun 4Aug 5Oct 5406.99

Key statistics

Enterprise value
28.26B
PEG ratio
2.96
Price / sales
8.35
Price / book
9.59
Dividend yield
0.26%
Payout ratio
9.88%
Revenue growth
8.70%
Free cash flow
345.56M
Total cash
464.10M
Total debt
313.90M
Return on equity
21.23%
Short % of float
3.38%
50-day average
368.70
200-day average
314.02

Financials — quick view

All financials
WST Revenue — quarterly 874.50M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
WST Net income — quarterly 214.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
WST EPS — quarterly 3.04
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

WST recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 20262.27———
Oct 29, 2026Sep 30, 20262.202.66+0.46+20.91%
Jul 23, 2026Jun 30, 20262.082.37+0.29+13.94%
Apr 23, 2026Mar 31, 20261.682.13+0.45+26.79%
Feb 12, 2026Dec 31, 20251.832.04+0.21+11.48%
Oct 23, 2025Sep 30, 20251.681.96+0.28+16.67%

Upgrades / downgrades

WST analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026CitigroupmainBuyBuy
Oct 30, 2026TD CowenmainBuyBuy
Oct 30, 2026BarclaysmainOverweightOverweight
Oct 30, 2026Evercore ISI GroupmainOutperformOutperform
Oct 13, 2026TD CowenmainBuyBuy
Oct 7, 2026BarclaysmainOverweightOverweight

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States

News

Your note

Sign in to keep a note on WST — it syncs with the Stock Master app.

Insider holders

WST insider holders
InsiderRelationLatest transactionDateShares held
BIRKETT BERNARD JOHNChief Financial OfficerConversion of Exercise of derivative securityFeb 17, 20257,520
BUTHMAN MARK ADirectorStock Award(Grant)May 3, 202644,308
FAVORITE ANNETTE FOfficerSaleSep 14, 202621,817
FEEHERY WILLIAM F.DirectorStock Award(Grant)May 3, 202632,519
GREEN ERIC MARKChief Executive OfficerConversion of Exercise of derivative securityFeb 17, 2026175,418
HOFMANN THOMAS WDirectorStock Award(Grant)May 5, 202544,637

Institution ownership

WST institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.55%6,651,7842.71BJun 29, 2026
Vanguard Capital Management LLC6.62%4,613,1341.88BJun 29, 2026
Vanguard Portfolio Management LLC5.76%4,015,7661.64BJun 29, 2026
FMR, LLC5.13%3,574,8161.46BJun 29, 2026
State Street Corporation4.81%3,348,6981.36BJun 29, 2026
Artisan Partners Limited Partnership3.46%2,411,792981.99MJun 29, 2026

Fund ownership

WST fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.22%2,242,860913.20MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.63%1,830,358745.25MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.20%1,530,738623.26MJun 29, 2026
Fidelity Contrafund1.61%1,120,323456.15MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Growth Index Fund1.35%940,525382.94MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.35%937,921381.88MSep 29, 2026